文献速递自身免疫性与大疱性皮肤病

抗p200类天疱疮发病率:法国全国性研究

Incidence of P200 pemphigoid: A nationwide study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2026-03-07

法国多中心回顾性研究采用新型抗层粘连蛋白β4细胞免疫检测法,在2018至2023年疑似抗p200类天疱疮血清中,93例双法检测显示CBIA阳性率91%显著高于免疫印迹47%(p<0.0001),估算法国发病率约0.23至0.83例/百万/年,提示该病远比既往估计常见。

要点

  • 抗LAMB4 CBIA检测抗p200抗体敏感性显著高于真皮提取物免疫印迹(91% vs 47%,p<0.0001)。
  • 法国抗p200类天疱疮估算发病率为0.23至0.83例/百万居民/年,约每年新增16至57例。
  • 该病发病率约为获得性大疱性表皮松解症的2至4倍,提示临床应提高认识。

核心结论

  • 抗p200类天疱疮在法国可能远比既往估计常见,新型抗LAMB4 CBIA可提高血清学检出率。

研究设计与样本

  • 多中心回顾性研究,于法国AIBD参考中心免疫实验室2018年1月至2023年3月进行,纳入116例IIF盐裂皮肤真皮侧着色且其他交界性AIBD阴性的患者血清。

主要发现

  • 93例血清同时行抗LAMB4 CBIA和真皮免疫印迹检测,CBIA阳性85例(91%),免疫印迹阳性44例(47%),差异有统计学意义(p<0.0001)。
  • 仅2例免疫印迹单独阳性,最终共110例患者检测到抗p200抗体。
  • 基于法国BP和天疱疮发病率(分别为21.7和1.85例/百万居民/年),估算抗p200类天疱疮发病率为0.23至0.83例/百万居民/年,对应法国每年约16至57例新发病例。
  • 该发病率约为获得性大疱性表皮松解症的2至4倍。

关键数值与推荐

  • 抗LAMB4 CBIA在93例双法检测血清中的阳性率为91%,真皮免疫印迹为47%(p<0.0001)。
  • 法国抗p200类天疱疮估算发病率为0.23至0.83例/百万居民/年。

临床怎么用

  • 对IIF盐裂皮肤真皮侧着色且其他交界性AIBD抗体阴性的疑似患者,可优先采用抗LAMB4 CBIA检测抗p200抗体以提高诊断敏感性。
  • 临床应认识到抗p200类天疱疮并非极罕见,发病频率可能高于获得性大疱性表皮松解症。

局限性

  • 本研究为回顾性设计,发病率估算基于相对BP和天疱疮频率的间接推算。
  • 仅纳入法国参考中心接收的血清,可能存在转诊偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-p200 pemphigoid (P200) is a rare subepidermal autoimmune blistering disease (AIBD) related to anti-laminin γ1 autoantibodies (Abs). It has been recently reported that laminin β4 was frequently recognized by sera from patients with P200. OBJECTIVES: To evaluate the incidence of P200 in France using a new recombinant anti-laminin β4 serological assay. METHODS: This multicentre retrospective study was conducted in the Immunology Laboratory of the French reference centre for AIBD from January 2018 to March 2023. Sera suspected of corresponding to P200 were tested using the new anti-LAMB4 cell-based immunoassay (CBIA) and/or immunoblotting (IB) on dermal extract. The incidence of P200 was then estimated based on its incidence rate relative to those of BP and pemphigus over the same period. RESULTS: 116 patients with sera labelling the dermal side of salt-split skin by IIF and negative for other junctional AIBD were recorded. Among them, 23 patients' sera had already been tested positive for P200 by dermal IB. Thus, 93 patients' sera were tested with both the anti-LAMB4 CBIA and IB: 85 were positive with the CBIA (91%) vs. 44 with IB (47%, p < 0.0001). Only two were positive with IB alone. Overall, 110 patients had anti-p200 Abs. Subsequently, we compared the frequency of serological detection of P200 to that of BP and pemphigus based on data from centres that exhaustively submitted their sera to our reference laboratory. According to the incidence of BP and pemphigus in France (21.7 and 1.85 cases per million inhabitants per year, respectively), the incidence of P200 was estimated to range from 0.23 to 0.83 cases per million inhabitants per year. This corresponds to approximately 16-57 new cases annually in France, which is approximately 2- to 4-fold more frequent than epidermolysis bullosa acquisita. CONCLUSIONS: This study shows that P200 may be much more frequent than initially estimated. Anti‐p200 pemphigoid incidence in France. Anti‐p200 pemphigoid is a rare autoimmune blistering disease involving the skin and mucous membranes. Since clinical features of anti‐p200 pemphigoid may be heterogeneous, the diagnosis relies on the detection of circulating anti‐p200 antibodies. Up to recently, the reference assay to identify anti‐p200 autoantibodies, restricted to specialized laboratories, was immunoblot analysis on dermal extract or on recombinant laminin γ1. A new anti‐laminin β4 cell‐based immunoassay (CBIA) has been recently developed for the detection of anti‐p200 antibodies. To assess the sensitivity of this new assay, we tested all sera labelling the dermal side of salt‐split skin by indirect immunofluorescence (IIF) and compared the results with those provided by the immunoblot analysis on dermal extracts. Given the high sensitivity of the anti‐laminin β4 CBIA, which is in fact close to that of ELISA for the detection of anti‐desmoglein and anti‐BP180 in pemphigus and bullous pemphigoid (BP), respectively; we then estimated the incidence of anti‐p200 pemphigoid relative to that of pemphigus and BP. One‐hundred‐and‐ten out of the 141 sera tested (71%) contained anti‐laminin β4 Abs when tested with the anti‐LAMB4 CBIA assay. Among the 93 sera analysed with both the anti‐LAMB4 CBIA and dermal immunoblotting, 85 were positive with the CBIA (91%) vs. 44 by immunoblotting (47%, p < 0.0001). According to the incidence of BP and pemphigus in France, the incidence of anti‐p200 pemphigoid was estimated at between 0.32 and 0.62 cases per million inhabitants per year, suggesting that anti‐p200 pemphigoid is much more frequent than initially reported.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Jouen F, Carrette M, Golinski ML, et al. Incidence of P200 pemphigoid: A nationwide study. J Eur Acad Dermatol Venereol. 2026. PMID: 41793217. doi:10.1111/jdv.70370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。